NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
World-first psilocin binge eating disorder trial reveals improvement in all patients
Swinburne University of Technology and Entropy Neurodynamics' world's first IV-infused psilocin binge-eating disorder trial has led to improvements in all participants.
The Maps We Lost
Psychedelics, Mysticism, and the Buried Feminine of Iran
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a…
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
CAMBRIDGE, Mass., September 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address…
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
LONDON & NEW YORK, September 15, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced…
Report from the FDA’s hearing on psychedelic drugs
We’re bringing you the highlights from today’s four hour-long hearing, held by the U.S.
Enveric Biosciences received a USPTO patent allowance for non-hallucinogenic mescaline-derived compounds in its EVM401 Series, marking the programme’s third US allowance.
The allowed claims are expected to cover methylone-inspired benzodioxole analogues developed for potential treatment of PTSD and other psychiatric and neurological disorders. Enveric said the compounds are designed to...
Xylo Bio has dosed the first participants in an Australian Phase 1 study of XYL-1001, a non-hallucinogenic selective 5-HT2A agonist for major depressive disorder.
The randomised, double-blind, placebo-controlled trial will assess XYL-1001’s safety, tolerability, pharmacokinetics and pharmacodynamic activity in healthy volunteers across single and multiple ascending dose cohorts...
MDMA-assisted Therapy for Fibromyalgia (NCT06066853, mdma)
This single-arm open-label trial (n=20) will assess the efficacy of MDMA-assisted psychotherapy for fibromyalgia patients.
The FDA reclassified NRx Pharmaceuticals’ preservative-free ketamine ANDA amendment from major to minor and set a revised GDUFA goal date of 10 November 2026.
The amendment concerns the drug vial for NRX-100, NRx’s preservative-free intravenous ketamine product. The FDA said the minor amendment would not require substantial agency resources, reducing the expected review bur...
Next-Generation Psychedelic Drug Development
This review (2026) discusses approaches to developing new psychedelic treatments for neuropsychiatric conditions, including depression, anxiety, and PTSD. It examines the strengths and limitations of existing testing ...
Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
This morning, LSD drug developer Definium Therapeutics shared positive topline data from its second Phase 3 study of its lead candidate, DT120, in generalised anxiety disorder (GAD). It’s the third positive Phase 3 re...
Scientists Engineered a “Humanized” Mouse to Study Psychedelics
PLUS using plant medicine with a chronic illness, drag queens, and Trump-shaped pressed pills. [...] Read More...
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a…